Advanced search
Publication Cover
Emerging Drugs Volume 5, 2000 - Issue 4
Journal homepage
42
Views
10
CrossRef citations to date
0
Altmetric
Review

‘Superbugs’: new antibacterials in the pipeline

Karen Bush The RW Johnson Pharmaceutical Research Institute, Raritan, NJ 08869, USA.
,
Mark Macielag The RW Johnson Pharmaceutical Research Institute, Raritan, NJ 08869, USA.
&
Joanna Clancy The RW Johnson Pharmaceutical Research Institute, Raritan, NJ 08869, USA.
Pages 347-365 | Published online: 24 Feb 2005

Bibliography

  • CARS O: Colonisation and infection with resistantGram-positive cocci. Epidemiology and risk factors. Drugs (1997) 54 (Suppl. 6):4–10.
  • FILE TM JR: Overview of resistance in the 1990s. Chest(1999) 115 (Suppl. 3):35–85.
  • WISER, ANDREWS JM: The in vitro activity and tentative breakpoint of gemifloxacin, a new fluoroquinolone. Antimicrob. Chemother. (1999) 44:679–688.
  • BARBER M: Methicillin-resistant staphylococci. J. Clin. Pathol. (1961) 14:385–393.
  • MOELLERING RCJ: Vancomycin-resistant enterococci. Clin. Infect. Dis. (1998) 26:1196–1199.
  • ••Overview of the mechanism of resistance and clinical use ofvancomycin against susceptible and resistant enterococci.
  • SAAH AJ, MALLONEE JP, TARPAY M, et al.: Relative resistance to penicillin in the pneumococcus. A prevalence and case-control study. J. Am. Med. Assoc. (1980) 243:1924–1927.
  • FELMINGHAM D, GRUNEBERG RN: The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J. Antimicrob. Chemother. (2000) 45:191–203.
  • PFALLER MA, JONES RN, DOERN GV, KUGLER K: Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicro-bial susceptibility patterns from the SENTRY antimi-crobial surveillance program (United States and Canada, 1997). Antimicrob. Agents Chemother. (1998) 42 (7):1762–1770.
  • •Isolation and identification of pathogenic bacteria from bloodstream infections in North American hospitals and their antimicrobial susceptibilities.
  • DIEKEMA DJ, PFALLER MA, JONES RN, et al.: Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USA, Canada and I2.tin America. Int. J. Antimicrob. Agents (2000) 13:257–271.
  • VINCENT J-L: Microbial resistance: lessons from the EPIC study. Intensive Care Med. (2000) 26:53–S8.
  • EDGEWORTH JD, TREACHER DF, EYKYN SJ: A 25-year study of nosocomial bacteremia in an adult intensive care unit. Crit. Care Med. (1999) 27:1421–1428.
  • •Historical analysis of clinical strains isolated from bloodstream infections in a single intensive care unit.
  • EDMOND MB, WALLACE SE, MCCLISH DK, et al.: Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin. Infect. Dis. (1999) 29:239–244.
  • SINGH N: Infectious diseases in the liver transplant patient. Semin. Gastrointest. Dis. (1998) 9:136–146.
  • KOLL BS, BROWN AE: The changing epidemiology of infections at cancer hospitals. Clin. Infect. Dis. (1993) 17 (Suppl. 2):S322–328.
  • RAAD I, ALRAHWAN A, ROLSTON K: Staphylococcus epidermidis: emerging resistance and need for alternative agents. Clin. Infect. Dis. (1998) 26:1182–1187.
  • JONES RN, LOW DE, PFALLER MA: Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant Gram-positive bacteria: the role of streptogramins and other newer compounds. Diagn. Microbic)]. Infect. Dis. (1999) 33:101–112.
  • BALTER SE, DOWELL SF: Update on acute otitis media. Curr. Opin. Infect. Dis. (2000) 13:165–170.
  • CARBON C, MOOLA S, VELANCSICS I, et al.: Efficacy of telithromycin (HAM 3647), a new once-daily antimi-crobial, in the treatment of community-acquired pneumonia. 40th Interscience Conference on Antimicro-bial Agents and Chemotherapy. Toronto, Canada (2000):2245.
  • HAGBERG L, TORRES A, VAN RENSBURG DJ, et al.: Efficacy and tolerability of telithromycin (-11111R 3647) vs. high-dose amoxicillin in the treatment of community-acquired pneumonia. 40th Intecscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (2000):2244.
  • CUNHA B: Current concepts in the antimicrobial therapy of community-acquired pneumonia. Drugs Today (1998) 34:107–1
  • HIRAMATSU K, HANAKI H, INO T, et al.: Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. (1997) 40:135–146.
  • CUT L, MURAKAMI H, KUWAHARA-ARAI K, et al.: Contri-bution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureusMu50 Antimicrob. Agents Chemother. (2000) 44:2276–2285.
  • BARTLETT JG, DOWELL SF, MANDELL LA, et al.: Practice guidelines for the management of community-acquired pneumonia in adults. Clin. Infect. Dis. (2000) 31:347–382.
  • ••Updated guidelines for the management of community-acquired pneumonia issued by the authors on behalf of the Infectious Diseases Society of America.
  • HENNEY JE: First drug for penicillin-resistant community-acquired pneumonia. JAMA (2000) 283:1679.
  • CHEN DK, MCGEER A, DE AZAVEDO JC, LOW DE: Decreased susceptibility of Streptococcus pneumo-niae to fluor oquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl. J Med. (1999) 341:233–239.
  • LAMB HM, FIGGITT DP, FAULDS D: Quinupristin/dalfopristin: a review of its use in the management of serious Gram-positive infections. Drugs (1999) 58:1061–1097.
  • ••Thorough review of the characteristics and clinical applica-tions of this drug combination.
  • MOELLERING RC, LINDEN PK, REINHARDT J, et al.: The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. J. Antimicrob. Chemother. (1999) 44:251–261.
  • LIVERMORE DM: Quinupristin/dalfopristin and linezolid: where, when, which and whether to use J Antimicrob. Chemother. (2000) 46:347–350.
  • NADLER H, DOWZICKY MJ, FEGER C, et al.: Quinupristin/dalfopristin: a novel selective-spectrum antibiotic for the treatment of multi-resistant and other Gram-positive pathogens. Clin. MicrobioL Newslett. (1999) 21:103–112.
  • JOHNSON A, LIVERMORE DM: Quinupristin/ dalfopristin, a new addition to the antimicrobial arsenal. Lancet (1999) 354:2012–2013.
  • WANG F-D, LIU I-M, LIU C-Y: In vitro activity ofquinupristin/dalfopristin and other antibiotics against ampicillin resistant Enterococcus faecium. Chin. Med. J. !Taipei] (2000) 63:119–123.
  • WERNER G, KLARE I, WITTE W: Association between quinupristin/dalfopristin resistance in glycopeptide-resistant Enterococcus faecium and the use of additives in animal feed. Eur. J. Clin. Microbic)]. Infect. Dis. (1998) 17:401–402.
  • CLEMETT D, MARKHAM A: Linezolid. Drugs (2000) 59:815–827.
  • •Good summary of the current data on the first oxazolidinone approved in the US.
  • DIEKEMA DJ, JONES RN: Oxazolidinones: a review. Drugs (2000) 59:7–16.
  • HAMEL JC, STAPERT D, MOERMAN JK, FORD CW: Linezolid, critical characteristics. Infection (2000) 28:60–64.
  • Inhibition of enzymes involved in bacterial cell wall synthesis. Sandler M, Smith HJ (Eds.), Oxford University Press, Oxford, UK (1989).
  • GEORGOPAPADAKOU NH: Penicillin-binding proteins and bacterial resistance to 13-lactams. Antimicrob. Agents Chemother. (1993) 37 (10):2045–2053.
  • •Review of penicillin-binding proteins as related to their mechanisms of action and resistance to I3-lactam antibiotics.
  • THORNSBERRY C, SAHM D: Antimicrobial resistance in respiratory tract pathogens: results of an interna-tional surveillance study. Chemotherapy (2000) 46 (Suppl. 1)15–23.
  • DRLICA K, ZHAO X: DNA gyrase, topoisomerase Wand the 4-quinolones. Microbiol. MoL Biol. Rev. (1997) 61 (3):377–392.
  • PIDDOCK LJ: Mechanisms of fluoroquinolone resistance: an update 1994–1998. Drugs (1999) 58 (Suppl. 2):11–18.
  • ••Updated review article on fluoroquinolone resistancemechanisms.
  • MORRISSEY I, GEORGE J: Activities of fluoroquinolones against Streptococcus pneumoniae Type II topoisomerases purified as recombinant proteins. Antimicrob. Agents Chemother. (1999) 43(10:2579–2585.
  • MORRISSEY I, GEORGE JT: Bactericidal activity of gemifloxacin and other quin olon es against Strepto-coccus pneumoniae. J. Antimicrob. Chemother. (2000) 45 (Suppl. S1):107–110.
  • BROSKEY J, COLEMAN K, GWYNN MN, et al.: Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae. J. Antimicrob. Chemother. (2000) 45 (Suppl. 51)95–99.
  • MILATOVIC D, SCHMITZ F-J, BRISSE S, et al: In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolon es against 8796 clinical bacterial isolates. Antimicrob. Agents Chemother. (2000) 44(4):1102–1107.
  • VANUFFEL P, DI GIAMBATTISTA M, COCITO C: The role of rRNAbases in the interaction of peptidyltransferase inhibitors with bacterial ribosomes. J Biol. Chem. (1992) 267:16114–16120.
  • CHOPRA I: Protein synthesis as a target for antibacte-rial drugs: current status and future opportunities. Exp. Opin. Invest. Drugs (1998) 7:1237–1244.
  • •Useful review of the newer structural classes of bacterial protein synthesis inhibitors.
  • SWANEY SM, AOKI H, GANOZA MC, SHINABARGER DL: The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob. Agents Chemother. (1998) 42:3251–3255.
  • XIONG L, KLOSS P, DOUTHWAITE S, et al.: Oxazolidinone resistance mutations in 23S rRNA of Escherichia coli reveal the central region of domain V as the primary site of drug action. J Bacteriol (2000) 182:5325–5331.
  • ZURENKO GE, TODD WM, HAFKIN B, et al.: Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid. 39th Intel-science Conference of Antimicrobial Agents and Chemotherapy. San Francisco, USA (1990848.
  • RASMUSSEN BA, GLUZMAN Y, TALLY FP: Inhibition of protein synthesis occurring on tetracycline-resistant, TetM-protected ribosomes by a novel class of tetracy-clines, the glycylcyclin es. Antimicrob. Agents Chemother. (1994) 38:1658–1660.
  • CHAMPNEY WS, TOBER CL: Structure-activity relation-ships for six ketolide antibiotics. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (2000):1820.
  • Strohl W (Ed.), M. Dekker, New York, NY, USA (1997):415–435.
  • ••Review of the properties and mechanism of action ofdaptomycin and related lipopeptide antibiotics.
  • CANEPARI P, BOARETTI M: Lip oteichoic acid as a target for antimicrobial action. Microbial Drug Resist. (1996) 2:85–89.
  • WOODCOCK JM, ANDREWS JM, BRENWALD NP, et al.: The in-vitro activity of faropenem, a novel oral penem. Antimicrob. Chemother. (1997) 39(0:35–43.
  • LEE VJ, HECKER SJ: Antibiotic resistance versus small molecules, the chemical evolution. Med. Res. Rev. (1999) 19:521–542.
  • CONON L, CORCORAN E, GRIFFITH D, et al.: Efficacy ofRWJ-54428 (MC-02,479) against methicillin-resistant Staphylococcus aureus (MRSA) endocarditis in the rabbit model. 37th Annual Meeting of the Infectious Diseases Society of America. Philadelphia, USA (1999) CID Publishing Number 76.
  • OHYE S, ABE T, ISHII C, et al.: R-115685. a novelparenteral carbapenem: in vitro antibacterial activity. 40th Intel-science Conference on Antimicrobial Agents & Chemotherapy. Toronto, Canada (2000):1230.
  • MAEDA N, HOSOKAWA T, SHARO S, et al.: R-115685: anovel parenteral carbapenem: preclinical safety studies. 40th Intel-science Conference on Antimicrobial Agents & Chemotherapy Toronto, Canada (2000):1234.
  • ZECKEL ML, PRESTON DA, ALLEN BS: In vitroactivities ofLY333328 and comparative agents against nosocomial Gram-positive pathogens collected in a 1997 global surveillance study. Antimicrob. Agents Chemother. (2000) 44:1370–1374.
  • •Comparative susceptibility profiles of the novel glycopep-tide LY-333328, vancomycin, teicoplanin, quinupristin-dalfopristin, oxacillin and penicillin tested against 1479 nosocomial Gram-positive pathogens isolated from 12 countries in 1997.
  • ARTHUR M, DEPARDIEU F, REYNOLDS P, COURVALIN P:Moderate-level resistance to glycopeptide LY333328 mediated by genes of the vanA and vanB clusters in enterococci. Antimicrob. Agents Chemother. (1999) 43:1875–1880.
  • SALEH-MGHIR A, LEFORT A, PETEGNIEF Y, et al.: Activityand diffusion of LY333328 in experimental endocar-ditis due to vancomycin-resistant Enterococcus faecalis. Antimicrob. Agents Chemother. (1999) 43:115–120.
  • GOLDSTEIN EJC, CITRON DM: Comparative in vitroactivity of gemifloxacin against Gram positive aerobes and anaerobes. 40th Intel-science Conference on Antimi-crobial Agents and Chemotherapy. Toronto, Canada (2000):2316.
  • HOBAN DJ, ZHANEL GG, KARLOWSKY JA: Activity ofgemifloxacin and comparative fluoroquinolones (FQs) against isolates of Streptococcus pneumoniae (SP N) with reduced susceptibility to ciprofloxacin. 40th Intel-science Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (2000):2315.
  • ALLEN A, BYGATE E, OLIVER S, et al.: Pharmacokineticsand tolerability of gemifloxacin (SB-265805) after administration of single oral doses to healthy volunteers. Antimicrob. Agents Chemother. (2000) 44 (6) :1604–1608.
  • Pay A, Allen A, Bygate E et al.: Multiple-dose pharmacoki-netics and tolerability of gemifloxacin following once-daily repeat oral 320 mg doses to healthy elderly volunteers. 40th Intel-science Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (20002265.
  • BIRD N, LEWIS A, MONTAGUE T, et al.: Assessment of theeffect of gemifloxacin on QTc interval in healthy volunteers. 40th Intel-science Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (2000):821.
  • THOMSON KS, SANDERS CC: The effects of increasinglevels of quinolone resistance on in-vitro activity of four quinolones. J. Antimicrob. Chemother. (1998) 42 (2) :179–187.
  • SHIMODA K, IKEDA T, OKAWARA S, KATO M: Possible relationship between phototoxicity and photodegra-dation of sitafloxacin, a quinolone antibacterial agent, in the auricular skin of albino mice. Toxkoi. Sci. (2000) 56 (2):290–296.
  • PANKUCH GA, JACOBS MR, APPELBAUM PC: Antipneu-mococcal activity of BMS-284756, a new des-F(6)-quinolone, compared with 10 other agents. 40th Intel-science Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (20001059.
  • GRADELSKI E, MINASSIAN B, STICKLE T, et al.: The in vitroactivity if the novel des-fluoro(6) quinolone BMS-284756 against Gram-positive and Gram-negative aerobic bacteria. 40th Intel-science Conference on Antimi-crobial Agents and Chemotherapy. Toronto, Canada (2000):1054.
  • TAKAHATA M, MITSUYAMA J, YAMASHIRO Y, et al.: In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone. Antimicrob. Agents Chemother. (1999) 43 (5) :1077–1084.
  • DAVIDSON RJ, DE AZAVEDO J, BAST D, et al.: The activity of BMS-284756, a novel des-(6)F-quinolone, against ciprofloxacin susceptible and non-susceptible Streptococcus pneumoniae. 40th Intel-science Confer-ence on Antimicrobial Agents and Chemotherapy. Toronto, Canada (2000):1053.
  • FUNG-TOMC J, HUCZKO E, KOLEK B, et al.: Serum bacterial inhibitory (SIT) and bactericidal (SBT) titers of a novel, des-fluoro(6) quinolone BMS-284756 in serum from healthy volunteers given a single dose of BMS-284756. 40th Intel-science Conference on Antimicro-bial Agents and Chemotherapy. Toronto, Canada (2000):2262.
  • GAJJAR DA, GRASELA DM, BELLO A, et al.: Safety,tolerability and pharmacokinetics of BMS-284756, a novel des-F(6)-quinolone, following single oral doses in healthy adult subjects. 40th Intel-science Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (2000):2259.
  • ROYCHOUDHURY S, MAKIN KM, MCINTOSH EJ, et al.: Invitro antibacterial activity of a series of nonfluoroqui-nolones (NFQs) against penicillin- and quinolone-resistant strains of Streptococcus pneumoniae. 39th Intel-science Conference on Antimicrobial Agents and Chemotherapy San Francisco, USA (1999):548.
  • ROYCHOUDHURY S, MAKIN KM, MCINTOSH EJ, et al.: Invitro antibacterial activity of a series of nonfluoroqui-nolones (NFQs) against quinolone-resistant isolates of methicillin -resistant Staphylococcus aureus. 39th Intel-science Conference on Antimicrobial Agents and Chemotherapy San Francisco, USA (1999)547.
  • BROWN SD, BARRY AL, FUCHS PC: In vitro antibacterialactivity of a series of novel nonfluoroquinolones (NFQs) against bacterial pathogens. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, USA (1990549.
  • MURPHY V, HANNAH-HARDY J, MURLI H, et al.: Prelimi-nary toxicology of a series of nonfluoroquinolones (NFQs). 39th Intel-science Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1999)554.
  • MALLALIEU NL, ELLIS DH, ZOUTENDAM PH, et al.: Preclinical pharmacokinetics of a series of nonfluoro-quinolones (NFQs). 39th Intel-science Conference on Antimicrobial Agents and Chemotherapy San Francisco, USA (1999):550.
  • GALES AC, JONES RN: Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. Diagn. Microbiol. Infect. Dis. (2000) 36:19–36.
  • BOUCHER HW, WENNERSTEN CB, ELIOPOULOS GM: Invitro activities of the glycylcycline GAR-936 against Gram-positive bacteria. Antimicrob. Agents Chemother. (2000) 44:2225–2229.
  • HOELLMAN DB, PANKUCH GA, JACOBS MR, APPELBAUMPC: Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumo-cocci. Antimicrob. Agents Chemother. (2000) 44:1085–1088.
  • PETERSEN PJ, JACOBUS NV, WEISS WJ, et al.: In vitro andin vivo antibacterial activities of a novel glycycicy-cline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. (1999) 43:738–744.
  • •Useful summary of the in vitro profile of GAR-936 and its activity in animal models.
  • PETERSEN PJ, WEISS WJ, LABTHAVIKUL P, BRADFORDPA: The post-antibiotic effect and time-kill kinetics of the glycylcycline, GAR-9 3 6 (TBG-MINO) and (PANINI-MINO.: 38th Intel-science Conference on Antimi-crobial Agents and Chemotherapy. Toronto, Canada (1998):F132.
  • VANOGTROP ML, ANDES D, CRAIG WA, VESGA 0: In vitro activity of two glycylcyclines (GAR-936 and WAY 152,288) against tetracycline-sensitive and -resistant bacteria. 38th Intel-science Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (1998):F133.
  • DOUTHVVAITE S, HANSEN LH, MAUVAIS P: Macrolide-ketolide inhibition of MIS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S r RNA. Mol Microbiol. (2000) 36:183–193.
  • •Effects of structural modifications of macrolides and ketolides on their ability to bind to and inhibit E. coli ribosomes modified by erm methylases.
  • PANKUCH GA, VISALLI MA, JACOBS MR, APPELBAUM PC:Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HAIR 3647 (RU 66647), a new ketolide, compared with suscepti-bilities to 17 other agents. Antimicrob. Agents Chemother. (1998) 42 (3):624–630.
  • REINERT RR, BRYSKIER A, LUTTICKEN R: In vitro activi-ties of the new ketolide antibiotics HMR3004 and HMR 3647 against Streptococcus pneumoniae in Germany. Antimicrob. Agents Chemother. (1998) 42 (6):1509–1511.
  • •Susceptibility profile and testing recommendations for telithromycin against penicillin- and erythromycin-susceptible and -resistant pneumococcal strains.
  • DUBOIS J, ST-PIERRE C: In vitro study of the minimal inhibitory concentrations (MIC) of telithromycin (HAIR 3647), macrolides and quinolones against Haemophilus, Streptococcus, Staphylococcus and Moraxelia strains obtained from upper and lower respiratory tract infections and from maxillary sinus aspiration. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (2000):2152.
  • LEROY B, RANGARAJU M: High in vitro susceptibility of the ketolide telithromycin (HMR 3647) in clinical isolates of key respiratory pathogens. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (2000):2224.
  • LEROY B, RANGARAJU M: Efficacy of telithromycin (HMR 3647), a new once-daily ketolide, in community-acquired pneumonia caused by atypical pathogens. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (20002225.
  • TELLIER G, HASSMAN J, LEROY B, et al.: Oral telithro-mycin (HMR3647) 800 mg once daily is well tolerated and as effective as oral clarithromycin 500 mg twice daily in community-acquired pneumonia (CAP) in adults. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (20002227.
  • PULLMAN J, CHAMPLIN J, LEROY B, SIDAROUS E: Oral telithromycin (HMR 3647) 800 mg once daily for 7–10 days is well tolerated and as effective as oral trovafloxacin 200 mg once daily for 7–10 days in community acquired pneumonia. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (2000)2230.
  • CAO Z, HAMMOND R, PRATT S, et al.: Mechanism ofaction for novel ketolide - ABT-773. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (19902135.
  • FUJIKAWA T, MIYAZAKI S, MATSUMOTO T, et al.: In vitroactivity of ABT-773, a new ketolide, against major respiratory pathogens. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (2000):2166.
  • WILLEY BM, TRPESKI L, PONG-PORTER S, et al.: The in vitro activities of ABT-773, telithromycin and other macrolides against Canadian streptococci. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (2000):2161.
  • JOHNSON C, BENJAMIN WH, JR, GRAY BM, et al.: In vitro activities of ABT-773, telithromycin and 8 other antimicrobials against erythromycin-resistant Streptococcus pneumoniae isolates from the respira-tory tracts of children. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (2000):2160.
  • OR YS, CLARK RF, WANG S, et al.: Design, synthesis and antimicrobial activity of 6-0-substituted ketolides active against resistant respiratory tract pathogens. J. Med. Chem. (2000) 43:1045-1049. •In vitro and in vivo structure-activity relationships among the ketolides, particularly comparing ABT-773 and telithromycin.
  • NEUHAUSER MM, PRAUSE JL, LI DH, et al.: In vitrobacteri-cidal activity of ABT-773, a new ketolide versus clarithromycin, azithromycin, ciprofloxacin, amoxicillin/clavulanate against penicillin/erythro-mycin sensitive and resistant Streptococcus pneumo-niae and Haemophilus influenzae. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1999):2139.
  • MITTEN M, MEULBROEK J, PAIGE L, et al.: Efficacies of ABT-773 and HMR-3647 against respiratory pathogens causing acute systemic infections in mice and lung infections in rats. 39th Interscience Conference on Antimi-crobial Agents and Chemotherapy San Francisco, USA (1999):2150.
  • PRADHAM RS, GUSTAVSON LE, LONDO DD, et al.: Single oral dose pharmacokinetics and safety of ABT-773 in healthy subjects. 40th Interscience Conference on Antimi-crobial Agents and Chemotherapy. Toronto, Canada (20002135.
  • TALLY FP, ZECKEL M, WASILEWSKI CC, et al.: Daptomycin: a novel agent for Gram-positive infections. Exp. Opin. Invest. Drugs (1999) 8:1223–1238.
  • •Updated review on daptomycin explaining the rationale for once-a-day dosing.
  • AMSTERDAM D, GORZYNSKI EA, BEAM TR, ROTSTEIN C: Susceptibility of bacteremic isolates of Gram-positive cocci to daptomycin and other antimicrobial agents. J. Antimicrob. Chemother. (1994) 33:1060–1063.
  • BROWN SD, BARRY AL, FUCHS PC: In vitro activity of daptomycin (Cidecinmi against contemporary Gram-positive clinical bacterial isolates from 11 North American medical centers (NAMC). 10th European Conference on Clinical Microbiology and Infectious Disease. Stockholm, Sweden (2000):P90:5/5.
  • LIEBOWITZ LD, SAUNDERS J, CHALKLEY LJ, KOORNHOF H: In vitmselection of bacteria resistant to LY146032, a new cyclic lipopeptide. Antimicrob. Agents Chemother. (1988) 32:24–26.
  • KAATZ GW, SEO SM, REDDY VN, et al.: Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis. Antimicrob. Agents. Chemother. (1990) 34:2081–2085.
  • TALLY FP, OLESON FP, BERMAN CL, DEBRUIN MF: Dap tomycin (Cidecinmj treatment for serious Gram-positive infections including endocarditis. 10th European Conference on Clinical Microbiology and Infectious Disease. Stockholm, Sweden (2000):WeP233:8/1.
  • KOTRA LP: Daptomycin. Curr. Opin. Anti-Infect. Invest. Drugs (2000) 2:185–205.
  • TALLY FP, DEBRUIN MF: Development of daptomycin for Gram-positive infections. J. Antimicrob. Chemother. (2000) 46:523–526.
  • DRUGEON H, BRYSKIER A, BEMER-MELCHIOR P, JUVIN ME: HMR1043: anew lip op ep tide antibacterial: in vitro properties. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (2000):2197.

Websites

  • http://www.fda.gov/cder FDA Center for Drug Evaluation and Research (Nov 2000).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.